Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 631-635

  Metzler, Kelli ^a   Drlica, Karl ^b   Blondeau, Joseph M ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Azalide; Macrolide; MPC; Pneumococcus

Indexed keywords

AGAR; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; GENE MUTATION; GEOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT PREVENTION CONCENTRATION; NONHUMAN; PRESCRIPTION; PREVALENCE; PROPENSITY SCORE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ATTENTION; AZITHROMYCIN; CANADA; CLARITHROMYCIN; ERYTHROMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84873587202     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks461     Document Type: Article

References (34)

1. Blondeau JM. Differential impact on macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae [editorial]. Therapy 2005; 2: 813-8.
2. Blondeau JM. The evolution and role of macrolides in infectious diseases. Exp Opin Pharmacother 2002; 3: 1131-51.
3. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
4. Balter MS, La Forge J, Low DE et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10: 3B-32B.
5. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Disease Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
6. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005; 59: 230-8.
7. Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents 2007; 30S: S135-8.
8. Davidson RJ, Chan CCK, Doern GV et al. Macrolide-resistant Streptococcus pneumoniae in Canada: correlation with azithromycin use. Clin Microbiol Infect 2003; 9: 240-1.
9. Croisier D, Etienne M, Piroth L et al. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 2004; 54: 640-7.
10. Cui J, Liu Y, Wang R et al. The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 2006; 194: 1601-8.
11. Murray PR, Baron EJ, Jorgenson J et al. Manual of Clinical Microbiology. Washington, DC: ASM Press, 2003.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard-Tenth Edition M02-A10. CLSI, Wayne, PA, USA, 2009.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
14. Blondeau JM, Zhao X, Hansen GT et al. Mutant prevention concentrations (MPC) of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433-8.
15. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33: S147-56.
16. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-74.
17. Canadian Bacterial Surveillance Network (CBSN). Macrolide-resistant pneumococci: Canadian Bacterial Surveillance Network, 1993-2009. http://microbiology.mtsinai.on.ca/data/sp/sp_2009.shtml#figure7 (2 October 2012, date last accessed).
18. Khashab MM, Xiang JX, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006; 22: 1997-2007.
19. Hansen G, Metzler KL, Drlica K et al. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 440-1.
20. Frisch AW, Tripp JT, Barrett CD Jr et al. Specific polysaccharide content of pneumonia lungs. J Exp Med 1942; 76: 505-10.
21. Fagon J, Chastre J, Trouillet JL et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 1004-8.
22. Cornick JE, Bentley SD. Streptococcus pneumoniae: the evolution of antimicrobial resistance to b-lactams, fluoroquinolones and macrolides. Microb Infect 2012; 14: 573-83.
23. Bergman S, Huikko S, Huovinen P et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 3646-50.
24. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288-97.
25. Baquero F, Negri M. Strategies to minimize the development of antibiotic resistance. J Chemother 1997; 9: 29-37.
26. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 441-6.
27. Smith H, Walters M, Hisanaga T et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or parC or gyrA mutation containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004; 48: 3954-8.
28. Blondeau JM, Hansen G, Metzler KL et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16: 1-19.
29. Hesje C, Tillotson GS, Blondeau JM. MICs, MPCs and PK/PDs: A match (sometimes) made in hosts. Expert Rev Respir Med 2007; 1: 7-16.
30. Blondeau JM. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol 2009; 20: 383-96.
31. Zhao X, Drlica K. A unified anti-mutant dosing strategy. J Antimicrob Chemother 2008; 62: 434-6.
32. Croteau D, Bergeron MG, LeBel M. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Antimicrob Agents Chemother 1988; 32: 561-5.
33. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin and telithromycin. Infect Dis Clin North Am 2004; 18: 621-49.
34. Abbott Laboratories. Product monograph: Biaxin. http://www.abbott.ca/static/cms_workspace/en_CA/content/document/BIAXIN-PM-20JUL 11.pdf (2 October 2012, date last accessed).